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experienced work showing minimal differences between
pulmonary and aortic homografts,9 and considering that
the pulmonary valve can withstand the higher mechani-
cal stress in systemic circulation,10 investigators had a
renewed interest in pulmonary homografts.11-20 However,
the use of pulmonary homografts remained in dispute
because various investigators reported contrasting
results. We started using pulmonary homografts for aor-
tic valve replacement in 1994, and in the present retro-
spective study we analyze our results to ascertain their
suitability.
Patients and methods
Patients. A total of 147 patients (101 male subjects) with
an age range from 5 to 68 years (mean, 32.2 ± 17.3 years)
underwent aortic valve replacement with either an aortic
(group 1, n = 103) or pulmonary homograft (group 2, n = 44).
The causes of aortic valve disease and associated lesions are
shown in Tables I and II. All the patients were assigned to
New York Heart Association (NYHA) class III or IV, and 26
patients had frank congestive heart failure.
With reports of excellent results, the suitability of aor-tic valve replacement with an aortic valve homo-
graft is well established.1-3 However, limited availability
of the aortic homografts is an important factor for their
restricted use. Pulmonary homograft was considered an
alternative substitute to the diseased aortic valve,4 but its
use was abandoned after initial trials.5,6 Considering the
excellent long-term results of pulmonary autografts in
the aortic position,7,8 which are further supported by the
Objective: Retrospective analysis was performed to determine the suitabili-
ty of pulmonary homograft as an aortic valve substitute.
Methods: From January 1994 through June 1999, 147 patients (mean age,
32.2 ± 17.3 years) underwent aortic valve replacement with either an aortic
homograft (group 1: n = 103, 25 fresh antibiotic preserved and 78 cryopre-
served) or a pulmonary homograft (group 2: n = 44, 11 antibiotic preserved
and 33 cryopreserved). In group 1 a scalloped subcoronary technique was
used in 64 patients, and a root replacement technique was used in 39
patients. In group 2 the scalloped subcoronary technique was used in 34
patients, and the root replacement technique was used in 10 patients.
Results: There were 131 operative survivors (group 1 = 91; group 2 = 40).
Follow-up ranged from 2 to 62 months. In group 1 none of the patients had
significant aortic regurgitation during the hospital stay. Three patients (all
having undergone the scalloped subcoronary technique) had moderate aortic
regurgitation after 6 to 32 months. In group 2, 10 patients (9 having under-
gone the scalloped subcoronary technique and 1 having undergone the root
replacement technique) developed significant regurgitation: 2 intraoperative-
ly, 5 in the early postoperative period before discharge from the hospital, and
3 during late follow-up 6 to 12 months postoperatively. Among the various
risk factors analyzed for overall homograft failure, use of a pulmonary
homograft was the single independent predictor of valve failure (odds ratio,
8.6; 95% confidence interval, 1.9-39; P = .006).
Conclusion: Pulmonary homograft, when inserted by means of a scalloped
subcoronary technique, is not a suitable aortic valve substitute. (J Thorac
Cardiovasc Surg 2000;120:148-55)
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Twelve patients had previously undergone various opera-
tions for the aortic valve (prosthetic aortic valve replacement
in 6, bioprosthesis-homograft aortic valve replacement in 3,
and aortic valve repair in 3).
Homograft preparation and preservation. The majority
of the homografts (n = 141) were obtained from cadaveric
donors. Six homografts were procured either from cardiac
transplant recipients or from multiorgan donors not suitable
for cardiac transplantation. The donor age ranged from 15 to
48 years. From cadaveric donors, hearts were procured with-
in 24 hours of death, and valves were dissected under sterile
conditions. Homografts were treated with antibiotic solu-
tion21 for 48 hours at 4°C. In initial experience, antibiotic-
preserved homografts were used directly within 40 days. In
the latter part of our experience, the homografts were cryo-
preserved in a preservative solution consisting of RPMI-1640
tissue culture medium (Roswell Park Memorial Institute tis-
sue culture medium 1640) with 10% fetal calf serum and 10%
dimethylsulfoxide. After sterile packaging, the homografts
were frozen gradually (–1°C/min) up to –80°C and then were
stored in the vapor phase of liquid nitrogen at a temperature
between –150°C and –190°C.
Surgical technique. Intraoperative transesophageal
echocardiography was performed in all the patients and,
depending on aortic root diameter, an appropriately sized
homograft was selected. Patients with an aortic root diameter
greater than 30 mm received a prosthetic valve. A standard
moderately hypothermic or normothermic cardiopulmonary
bypass with antegrade, cold, hyperkalemic blood cardiople-
gia was used in all the cases.
Among patients in group 1, in 64 patients a scalloped sub-
coronary implantation technique, as described by Ross,22 was
used. In 35 patients the root replacement technique of
Elkins23 was used. In 4 patients both the diseased aortic valve
and the ascending aorta were replaced by a valved homograft
conduit. Among patients in group 2, the scalloped subcoro-
nary technique was used in 34 patients, the root replacement
technique was used in 9 patients, and a valved homograft
conduit was used in 1 patient. For the purpose of analysis,
patients in whom a valved homograft conduit was used were
included in the root replacement group. In group 1, 25
patients received an antibiotic-preserved valve, and 78
patients received a cryopreserved valve. In group 2,
11 patients received an antibiotic-preserved homograft, and
Table I. Cause of aortic valve disease in patients undergoing aortic valve replacement with an homograft 
(n = 147)
Group 1 (n = 103) Group 2 (n = 44) Total (n = 147)
Cause No. % No. % No. %
Rheumatic heart disease 69 67 36 80 105 71
Bicuspid aortic valve 12 12 2 7 14 10
Degenerative aortic valve disease 14 14 3 7 17 12
Prosthetic valve endocarditis 4 4 2 5 6 4
Marfan syndrome 2 2 0 0 2 1
Annuloaortic ectasia 1 1 1 2 2 1
Ascending aortic aneurysm with aortic regurgitation 1 1 0 0 1 1
Total 103 100 44 100 147 100
Table II. Additional significant preoperative morbid conditions (n = 147)
Group 1 (n = 103) Group 2 (n = 44) Total (n = 147)
Associated morbid condition No. % No. % No. %
Significant mitral valve disease 43 42 22 50 65 44
Significant tricuspid valve disease 6 6 1 2 7 5
Left ventricular dysfunction (ejection fraction <40%) 41 40 16 36 57 39
Ischemic heart disease 6 6 0 0 6 4
Native aortic valve endocarditis 9 9 4 9 13 9
Previous cardiac procedure (CMV, BMV, AVBD) 16 16 4 9 20 14
Previous aortic valve operation 9 9 3 7 12 8
Diabetes mellitus 8 8 4 9 12 8
Atrial septal defect 1 1 0 0 0 1
Supravalvular aortic stenosis 1 1 0 0 1 1
Pseudoaneurysm of ascending aorta 1 1 0 0 1 1
CMV, Closed mitral valvotomy; BMV, balloon mitral valvotomy; AVBD, aortic valve balloon dilatation.
150 Choudhary et al The Journal of Thoracic and
Cardiovascular Surgery
July 2000
33 patients received a cryopreserved homograft. In 73
patients 81 additional procedures were performed (Table III).
At the completion of the procedure, cardiopulmonary
bypass was discontinued, and transesophageal echocardiog-
raphy was performed to assess the valve function.
Follow-up and assessment of valve function. A transtho-
racic echocardiographic evaluation was carried out 5 to 7
days postoperatively before discharge from the hospital.
Subsequently, patients were followed up in the outpatient
department, and transthoracic-transesophageal echocardiog-
raphy was performed 1, 3, and 6 months postoperatively and
then at every 6 months. On echocardiography, aortic regurgi-
tation was graded according to published criteria.24
Significant aortic regurgitation was considered with aortic
regurgitation of grade III or IV severity. Valve-related events
were reported as per prescribed guidelines.25
Statistical analysis. Continuous or interval-related vari-
ables were expressed as mean values ± SD. Categoric vari-
ables were expressed as percentages. Groups were compared
by the χ2 and Student t tests. Actuarial estimates have been
calculated by using the Kaplan-Meier technique.26
The incidence of homograft failure was examined in relation
to a variety of variables (Appendix I). The native anulus sizes
and homograft sizes were also categorized (ie, <25 mm and
≥25 mm). Crude relative risks (RRs) with 95% confidence
intervals (CIs) were computed. Logistic regression models
based on the generalized estimating equations described by
Liang and Zeger27 were used to generate adjusted odds ratios
as estimates of adjusted RRs with appropriate 95% CIs.
Variables were included in the final model for adjustment if
their presence in the logistic models altered the crude RR by at
least 10%, except for age, year of surgery, cardiopulmonary
bypass time, and aortic crossclamp times, which were includ-
ed in all models. Statistical analysis was performed with the
use of the SAS system (SAS, Inc, Cary, NC).
Results
Early results
Early mortality. In group 1, there were 12 early deaths
(12%). Cause of death included low-output syndrome 
(n = 4), intractable ventricular arrhythmia (n = 2), pro-
gressive left ventricular dysfunction (n = 3), infective
endocarditis (n = 2), and catastrophic hemorrhage (n = 1).
In group 2, 4 (9%) patients died during the hospital stay,
and the causes included low-output syndrome (n = 1),
ventricular arrhythmia (n = 1), infective endocarditis (n =
1), and progressive left ventricular dysfunction (n = 1).
Survivors. Among survivors, 91 (69%) patients
received an aortic homograft (23 antibiotic-preserved
and 68 cryopreserved homografts), and 40 (31%)
patients received a pulmonary homograft (10 antibiot-
ic-preserved and 30 cryopreserved homografts).
Profiles of these patients are shown in Table IV.
Valve function. None of the patients who received an
aortic homograft had significant regurgitation during
the hospital stay.
Two patients who underwent aortic valve replace-
ment with a cryopreserved pulmonary homograft
placed by means of a scalloped subcoronary tech-
nique had significant aortic regurgitation intraopera-
tively, as detected by transesophageal echocardiogra-
phy. In both patients the homograft was replaced with
a mechanical prosthesis. In addition, 2 more patients
(patient 5 and 7, Table V) showed signs of mild aortic
regurgitation on intraoperative transesophageal
echocardiography. In the remaining patients there was
no aortic regurgitation.
At the time of discharge, 5 patients had moderate to
severe aortic regurgitation. All of these patients
received a pulmonary homograft by means of a scal-
loped subcoronary technique. The profile of patients
with early valve failure is shown in Table V. Two of
these patients (patients 5 and 7, Table V) had a large
aortic anulus, with diameters of 28 and 30 mm, respec-
tively. Two other patients had mild aortic regurgitation
at the time of discharge.
Late results. Follow-up ranged from 2 to 62 months
(mean follow-up: group 1, 24.5 ± 13.2 months; group
2, 23.4 ± 12.9 months) and was 97% complete.
Table III. Additional procedures performed in patients undergoing aortic valve replacement with a homograft 
(n = 147)
Group 1 (n = 103) Group 2 (n = 44) Total (n = 147)
Additional procedure No. % No. % No. %
Mitral valve repair 24 23 15 34 39 27
Open mitral commissurotomy 20 19 6 14 26 18
Tricuspid valve repair 6 6 1 2 7 5
Coronary artery bypass grafting 6 6 0 0 6 4
Redo mitral valve replacement with a bioprosthesis 1 1 0 0 1 1
Repair of pseudoaneurysm of ascending aorta 1 1 0 0 1 1
Closure of atrial septal defect 1 1 0 0 1 1
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Late mortality. In group 1 there were 3 (3%) late
deaths. Two patients died 3 and 5 months postopera-
tively as a result of Aspergillus-induced endocarditis.
Another patient died as a result of progressive left ven-
tricular dysfunction after 24 months.
There were 4 (9%) late deaths in group 2. One patient
(patient 1, Table V) died after 2 months as a result of
congestive heart failure. Mediastinitis with secondary
hemorrhage was the cause of death in 1 patient.
Endocarditis (Aspergillus-induced endocarditis in 1,
and Staphylococcus aureus–induced endocarditis in the
other) was the cause of late mortality in 2 patients.
Valve-related events and clinical status. There were 3
reoperations. Two patients (1 in group 1 and 1 in group
2) were reoperated on for fungal endocarditis
(Aspergillus) 6 and 5 months postoperatively, respec-
tively. Both the patients died as a result of overwhelm-
ing fungal infection.
One patient (patient 5, Table V) developed severe
aortic regurgitation after 6 months and was reoperated
on after 18 months. The pulmonary homograft was
replaced with a mechanical prosthesis. At reoperation,
valve cusps were found to be thin and transparent.
There was no coaptation with each other. All the cusps
Table IV. Profile of operative survivors (n = 131)
Homograft
Variable Aortic (n = 91) Pulmonary (n = 40) Aortic vs pulmonary
Mean age ± SD (y) 34.4 ± 17.3 29.0 ± 17.4 t = 1.6, P = .7
Mean follow-up ± SD (mo) 24.5 ± 14.2 23.4 ± 12.9 t = 0.4, P = .7
CPB time (min) 128.4 ± 34.7 130.1 ± 26.6 t = 0.3, P = .6
Aortic crossclamp time (min) 101.3 ± 26.9 105.4 ± 21.1 t = 0.8, P = .5
Cause
Rheumatic 68 34 χ2 = 1.6, P = .3
Nonrheumatic 23 6
Physiologic lesion
Aortic stenosis 26 6 χ2 = 2.1, P = .2
Aortic regurgitation 65 34
Aortic anulus size
<25 mm 77 31 χ2 = 0.5, P = .5
≥25 mm 14 9
Left ventricular dysfunction (ejection fraction < 40%) 32 12 χ2 = 0.1, P = .7
Mitral valve disease 40 19 χ2 = 0.0, P = 1.0
Preoperative endocarditis 9 6 χ2 = 0.3, P = .6
Reoperation 6 3 χ2 = 0.0, P = 1.0
Preservation
Antibiotic preserved 23 10 χ2 = 0.0, P = 1.0
Cryopreserved 68 30
Technique
Scalloped subcoronary 56 31 χ2 = 2.5, P = .1
Root replacement 35 9
CPB, Cardiopulmonary bypass.
Table V. Profile of operative survivors who had early valve failure
Patient Type of Preservation of
No. Age (y) Sex Cause Lesions homograft homograft Technique Outcome
1 62 M Rheumatic AR Pulmonary Antibiotic SS
2 15 F Rheumatic AR Pulmonary Antibiotic SS
3 20 F Rheumatic AR Pulmonary Antibiotic SS
4 15 F Rheumatic AR Pulmonary Cryopreservation SS
5 15 M Rheumatic AR Pulmonary Cryopreservation SS
6 12 M Rheumatic AR Pulmonary Cryopreservation SS
7 19 F Rheumatic AR Pulmonary Cryopreservation SS
AR, Aortic regurgitation; SS, scalloped subcoronary.
Moderate AR at discharge, severe AR after 2 mo, death
Moderage AR at discharge, severe AR at 6 mo
Severe AR at operation, replacement with mechanical 
prosthesis
Severe AR at operation, replacement with mechanical 
prosthesis
Moderately severe AR at discharge, reoperation after 18 mo
Moderate AR at discharge, moderate AR at 18 mo
Moderate AR at discharge, severe AR after 6 mo
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were intact. Microscopically, the endothelial and mes-
enchymal cells were characteristically absent, and only
the fibrous skeleton of the valve was left in situ.
Clinically, 102 patients are currently in NYHA class
I, and 12 are in class II (left ventricular dysfunction in
8, significant mitral regurgitation in 2, and significant
aortic regurgitation in 2). Six patients are in NYHA
class III (left ventricular dysfunction in 5 and severe
mitral regurgitation in 1).
Valve function. In patients with moderate aortic
regurgitation at discharge, the severity increased, and 4
of them had severe aortic regurgitation over a period of
2 to 6 months (1 underwent a second operation and 1
died). In 1 patient (patient 6, Table V) the degree of aor-
tic regurgitation remained the same after a follow-up of
18 months.
An additional 6 patients (3 in group 1 and 3 in group
2) had significant aortic regurgitation over a follow-up
Table VI. Profile of patients who had late valve failure
Patient Age Type of Preservation
No. (y) Sex Cause Lesion homograft of  homograft Technique Comments
1 25 M Bicuspid AR Pulmonary Antibiotic Scalloped 
aortic valve subcoronary
2 25 M Rheumatic AR Aortic Cryopreservation Scalloped 
subcoronary
3 17 M Rheumatic AR Pulmonary Antibiotic Scalloped 
subcoronary
4 19 M Bicuspid Aortic Aortic Cryopreservation Scalloped 
aortic valve stenosis subcoronary
5 12 M Rheumatic AR Pulmonary Cryopreservation Root 
replacement
6 24 F Rheumatic AR Aortic Cryopreservation Scalloped 
subcoronary
AR, Aortic regurgitation.
Moderate AR after 12 mo
Moderate AR after 32 mo
Mild AR at discharge, moderate AR at 6 mo
Moderate AR after 12 mo
Mild AR at discharge, moderate AR at 12 mo
Moderate AR after 14 mo
Fig 1. Probability of freedom from significant aortic regurgitation (Kaplan-Meier) in operative survivors who either
received an aortic or a pulmonary homograft.
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of 6 to 36 months. Profiles of these patients are shown
in Table VI. Two of these patients (patients 3 and 5,
Table VI) had mild aortic regurgitation at the time of
discharge.
Freedom from significant aortic regurgitation in
operative survivors who received either an aortic or a
pulmonary homograft is shown in Fig 1.
Various risk factors were analyzed for overall homo-
graft failure (Appendix I). In univariate analysis (Table
VII) the use of a pulmonary homograft was a signifi-
cant risk factor for valve failure (crude RR, 9.7; 95%
CI, 2.3-35; P = .0005). The mean age of patients with
valve failure (21.5 ± 13 years) was significantly less
than that of those without valve failure (34 ± 17.5
years; t = 2.5; P = .005). However, in multiple regres-
sion analysis, use of a pulmonary homograft was the
single independent predictor of valve failure (odds
ratio, 7.4; 95% CI, 1.7-34; P = .007). Although the
majority of patients with valve failure had undergone
aortic valve replacement with a scalloped subcoronary
technique, a statistical correlation could not be estab-
lished because of the small number of patients.
Discussion
In our experience the use of a pulmonary homograft
to replace the diseased aortic valve was associated with
a significantly higher risk of valve failure. Although
other factors, such as age, cause, physiologic lesion,
use of amphotericin in homograft treatment, and surgi-
cal technique,3-5,20 have also been considered important
factors for homograft failure, we did not find any cor-
relation between these factors and the risk of homo-
graft failure.
Investigators have found that the ultrastructure of the
pulmonary homograft cusps and that of the aortic
homograft cusps is the same, with no substantial ultra-
structural difference.9,15 Although the pulmonary
leaflets are thinner than the aortic leaflets, with a less-
er content of elastic tissue in the ventricular layer, the
ultimate tensile strength was similar for both the aortic
and pulmonary valves.15 Gorczynski and colleagues10
have also demonstrated that breaking strain for the aor-
tic and pulmonary valve leaflets is similar because even
though the pulmonary leaflets are thinner, they do have
greater tensile strength than the aortic leaflets.
Pragliola and colleagues17 have further demonstrated a
larger coapting surface with a pulmonary valve than
with an aortic valve. Despite these favorable morpho-
logic and mechanical characteristics, investigators18,28
were reluctant to use pulmonary valves in the systemic
circulation because of concern about the durability of
the pulmonary structures subjected to systemic pres-
Table VII. Univariate analysis of various risk factors for homograft failure
Variable n Homograft failure Crude RR 95% CI P value
Sex
Male 86 9 1.2 0.3-5 .8
Female 45 4
Cause
Rheumatic 102 11 1.6 0.3-60 .8
Nonrheumatic 29 2
Lesion
Aortic stenosis 32 1 0.2 0.02-1.9 .3
Others 99 12
Left ventricular dysfunction 44 6 1.8 0.5-6.5 .5
Mitral valve disease 64 5 0.6 0.2-2.3 .6
Previous procedure 17 3 2.2 0.2-10.5 .5
Aortic anulus
≥25 mm 23 3 1.4 0.02-6.6 .8
<25 mm 108 10
Preservation of homograft
Antibiotic preserved 33 5 2.0 0.7-7.5 .4
Cryopreserved 98 8
Technique
Scalloped subcoronary 87 12 6.9 0.8-60 .07
Root replacement 44 1
Type of homograft
Pulmonary 40 10 9.7 2.3-35 .0005
Aortic 91 3
sure. Although both clinical and experimental stud-
ies7,8,10 have shown the suitability of the pulmonary
autografts in systemic circulation, the results could not
be reproduced with the pulmonary homografts. Lack of
antigenicity and absolute vitality of the autograft may
be the chief contributors to the excellent results
obtained by use of an autograft. However, another sig-
nificant difference appears to be the use of different
techniques for insertion of a pulmonary autograft and a
pulmonary homograft. In recent decades, the root
replacement technique is the preferred technique for
autograft insertion, whereas most of the investigators
have used either a scalloped subcoronary technique or
intra-aortic cylinder technique for pulmonary homo-
graft insertion.
Similar to the experience of others,14,15,17,20 we also
had a high failure rate with pulmonary homografts
inserted by means of a scalloped subcoronary tech-
nique. There were fewer failures when a root replace-
ment technique was used, which was also evidenced by
others.17 We believe that because of the delicate and
frail structure of the pulmonary homograft, it is very
difficult to maintain the normal geometry of the pul-
monary homograft during intra-aortic implantation, by
using either the scalloped subcoronary or cylinder tech-
nique. The same belief is shared by others.17,20 This is
evident from early failures of implanted pulmonary
homografts in our experience and the experience of
other investigators.4,15-20 In most of these re-
ports4,15-20,29 either prolapse of one of the cusps or cen-
tral regurgitation as a result of altered geometry was
responsible for the failure of the pulmonary homograft.
Besides early failure, 3 of our patients who had
received a pulmonary homograft had late valve fail-
ure. Two of these (patients 3 and 5, Table VI) had mild
aortic regurgitation at the time of discharge. Thus
these failures may also be considered results of the
altered geometry of the homograft, leading to pro-
gressive aortic regurgitation. Other investigators have
found intrinsic valve failure in the form of cusp rup-
ture or cusp perforation as a cause of late homograft
failure.5,20,30 Although pulmonary valves are identical
to aortic valves in respect to ultrastructural and
mechanical qualities, intrinsic structural failure is
reported more commonly and after a shorter interval
with a pulmonary homograft. Mair and colleagues20
postulate that because of the delicate nature of the
pulmonary homograft, minor alterations in the geom-
etry of the valve do occur at the time of intra-aortic
implantation. These changes are so subtle that they
are overlooked easily and may not necessarily pro-
duce graft incompetence in the early phase but lead to
minimal unphysiologic stress to the cusps. This mini-
mal unphysiologic stress, in a subsequent time course,
can cause material fatigue and, consequently, struc-
tural failure of the valve.
The size of the used homograft is another important
consideration. Because the pulmonary homografts are
inherently larger than the aortic homografts, they
might be selected for implantation in the large, often
dilated anulus, the pathology of which would favor
continued dilatation and early homograft failure. Two
of our patients (patients 5 and 7, Table V) had a large
anulus (28 and 30 mm, respectively), and homografts
with one size smaller than the aortic root were insert-
ed, as is our practice during insertion of an aortic
homograft. Both these homografts failed as a result of
central incompetence. Others11,15 have suggested a
pulmonary homograft slightly larger than the aortic
root to counteract this. They believe that minor
changes in homograft geometry at the time of insertion
are neutralized by the choice of a large homograft due
to availability of a larger coaptation surface. Another
option is reducing and remodeling the aortic anu-
lus31-33 at the time of implantation of the homograft.
However, we believe that in patients with a large aor-
tic anulus, pulmonary homograft valve should not be
used, and if required, a root replacement technique
with a homograft slightly larger than the native root is
a better option in such conditions.
To conclude, we believe that a pulmonary homograft,
when inserted by means of a scalloped subcoronary
technique, is not a suitable aortic valve substitute.
Although the root replacement technique appears safe,
a larger and longer study is required to judge its suit-
ability.
We thank Mr Rajvir Singh, MSc (Biostat), for statistical
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Appendix 1. List of variables analyzed as risk factors
for homograft failure
Preoperative variables
• Age 
• Sex
• Cause: rheumatic versus nonrheumatic
• Physiologic lesion: aortic stenosis versus others
• Associated mitral valve disease
• Left ventricular dysfunction
• Endocarditis
• Previous cardiac procedure
• Previous aortic valve surgery
• Aortic anulus (<25 mm vs ≥25 mm)
Preoperative variables
• Year of operation (1993-1999)
• Type of homograft: aortic versus pulmonary
• Preservation of homograft: cryopreserved versus antibiotic preserved
• Technique of graft insertion: scalloped subcoronary versus root
replacement
• Cardiopulmonary bypass time
• Aortic crossclamp time
• Homograft size (<25 mm vs ≥25 mm)
